this this everybody. morning. Thanks, with begin you commercial us We'll Rubraca. Anna. Welcome, update We joining appreciate a morning for
growth X% and describe growth lower distributors in revenue will were higher shortly. to with for inventory Our and This our QX, Dan quarter We approximately occurred goods QX this gross-to-net U.S. quarter-over-quarter represented $XX.X which levels as global and of adjustments detail pleased year-over-year. free more despite our was in million. $XX slightly XX% million, revenue of
sales We maintenance second-line are more market ovarian to overall. cancer continue growing focus broadly and on expand to specifically Rubraca working the
multiple of quarter-over-quarter ingrained have treatment. these to U.S. our the to calls, evidenced to our the several maintenance opposed effort initiatives share on as last mentioned initiatives we've compete all habit underway for watch-and-wait quarterly growth by believe we sales are against growth. contributing to As and inroads We active market in make
like evaluating we of outside vendors. progress course amount of over to a from quarter I'd searches information know there's acknowledge interest also of that sales great the through the in sales the
We our actual data have sales And access historically extrapolate vendors used algorithms these actual our not a available particularly capture amount from specialty blocked to result, through our distributors. a accurately as by data. of sales, small the the to may
predictive vendors As value data provided a be result, the by of imperfect. times at outside the sales may these
we've this couple To attempt of decided alleviate to changes. make situation, a to
and these will our to First, with specialty changes to accurate be our we quarter, fourth in directionally are outside purchase the at provided data effective distributors fully we perfectly allow contracts to contractual hopefully occur data helpful. over pharmacies be but more These sales vendors. and be amending the third the specialty any least anticipate guarantees hardly quarter. will will that that it This
for guidance sales a remainder sales expectation our more of the which That minimum, will in rest least providing are Dan the year. at provide we at here, shortly. for you, the time first will the give of for the Second, year, detail
the to Turning EU.
we in to leave XXXX to versus sales to QX in it Our a to launch Briefly, ex QX shipments result, was U.S. stocking sales as $X.X detail. I'll QX and expect due March. million. And this QX. U.S. in Dan more decline ex discuss sequential occurred in in this were versus that QX increase
anticipate progress are and markets. XXXX. receive and EU in private maintenance include we of XXXX into and in anticipate pay as XXXX the in countries treatment label of In and second and U.K. on expanded therefore remainder EU end Germany we line-related March, revenue late Commission we both launched As XXXX the reimbursement the a for in reminder, the We at data. the launching seeing European increasing to the in based additional the the January, now an indication ARIELX for market approved in Rubraca
I'll turn most program advanced in our now to prostate setting. near-term cancer the development
moving As path and to time into ongoing are on review the may the have know, regulatory you enroll data and again, today TRITONX we which study I'd date to to Rather X have to in we the than available program, our continue have website, TRITON the take studies studies. TRITONX, the designs we forward. like patients focus we presented and on both
the We by XX% initial at a blinded confirmed data ESMO year. by central with consistent X and rate in cancer The assessment October response independent last in that X were of mutation, TRITON number. metastatic evaluable TRITONX with Rubraca studies showed objective presented from investigator results data first XX patients in BRCA or the reported castration-resistant prostate review initial
evaluable or response those PSA with tumors. BRCA response men observed Preliminary solid was in antigen, indication with this data PSA, Rubraca In consistent in addition, were in ovarian patients prostate-specific with mutation. other the rate and XX% patients for safety in observed the confirmed XX cancer
X therapy Breakthrough As least the X Rubraca for Rubraca basis metastatic prostate monotherapy granted a Therapy taxane-based treatment designation patients with data the designation for were have adult cancer these second to and or Therapy receptor-targeted chemotherapy. X by castration-resistant the reminder, received In mutant October who as was BRCA prior androgen FDA. a Breakthrough of XXXX, granted at
to Breakthrough designation, TRITON Rubraca's Therapy a of provide on to result program updates a opportunity we clinical basis. the FDA the on the have As regular
updates TRITON regulatory largely to and active dialogue is maintain to do an our FDA provide update ongoing serves to informational rapid We around Later since be our program. hope may data. familiar that program. these this will month, we on the the update a more FDA with intend FDA This facilitate an review
such had call. already the conference to quarter, update to completed was this our the of and update we Last QX timing that prior FDA submitted
RECIST completed response PSA this FDA the with rates ESMO at have consistent our that you, we update. before and I both the tell occurs in update already call are time XXXX. today's quarter, presented can This the data to however,
accelerated file treatment from planned of NDA supplemental approval mutated to submission castration-resistant as for our Accordingly, metastatic prostate XXXX. we quarter fourth Rubraca on remain the any BRCA for during cancer track
Finally, also it data supportive accepted been on in in session be included based will but pleased responses have TRITONX responses, late PSA a We're as discussion share poster be Barcelona the September. will also data. at ESMO RECIST to that for
Additionally, XX, we will these Barcelona other results analyst well and event presented host September data as on investor Sunday, congress. as in at the discuss our an
clinic. now highlight trials Rubraca a additional I'd then lucitanib, in turn to the Next, and to few which like is
pan-tumor last in is across quarter support patients to that the introduced homologous study mutations registration for Our we deleterious designed recombination or Rubraca gene. with basket and repair planned solid tumors
clinical FDA with XXXX. about dialogue encouraging remain nivolumab. to with and more We about look enthusiastic we details this study an initiate providing had by have Rubraca and the both combination its design. about ongoing year will forward study our have We and our lucitanib very the collaboration end We I'll with Squibb, with for updates of combination. begin Bristol-Myers Rubraca studies anticipate
includes This first with Opdivo Rubraca. combination combination we'll the maintenance advance. We're the previously Rubraca new prostate of cancer other trial Phase moving combination trials, Rubraca CHECKMATE advanced in XXXX. a gastric first-line which forward initiation and planned II treatment time QX III BMS-sponsored advanced continue of with with in trial Phase exploring in the ARIES cancer; ovarian cancer, pleased which that be castration-resistant and is Opdivo to of announce Phase II cancer; in advanced a and ATHENA X the trial discussed ovarian the We the to a XKD metastatic Yervoy is that for study triplet
highlights completing X,XXX-patient are pleased by the enrollment following: in this enrollment combination, Some study midyear ATHENA, with XXXX. For anticipate Rubraca-Opdivo particularly pace include the of and from Clovis-sponsored the we
opened showing with combining will an enrollment ARIES, in the inhibitor focus For patients quarter, a PD-X we deficiencies. cancer platinum-sensitive on patients PARP a second a HR of believe in and ovarian the women and and advanced study potential in biomarker-negative primary important with be with this benefits
meeting report this at We initial medical expect from to a year. data next study
to let's move to up Rubraca wrap the turn to SEASTAR. lucitanib, And on and
in Our portion combination enrolling studies, the the PARP multiple preclinical of Ib/II suppression Ib and which of angiogenesis rucaparib is currently cancer, study for and rationale following combination ovarian the clinical single-arm Clovis-sponsored with providing The in cohorts: inhibition studies Phase demonstrated activity has strong dose-finding currently of combination Phase that in study. combination. Rubraca a includes include lucitanib impressive this
highlights solid a combination of monotherapy the our but than tumors with urothelial cancers sacituzumab therapy XX of Rubraca breast cancer studies, govitecan are in expected more Immunomedic's in are metastatic for end. by clinical Also, there in of enrolling combination to variety cancer, rucaparib or metastatic year advanced investigator-sponsored approved monotherapy underway. or and combination patients platinum-resistant begin also studies treatment some relapsed triple-negative These is of ovarian the
receptors an is through X, kinases, through investigational and Lucitanib including fibroblast of factors vascular lucitanib. X beta growth inhibitor endothelial X. -- receptors tyrosine X to and factor alpha factor Now receptors growth platelet-derived growth
We discussed lucitanib, with targeting believe development well compelling these PD-X. combined we've simultaneously with PD-X FGF proliferation resistance lucitanib large opportunity We anti-VEGF to relevant as pathways by a potential the for represents a by which and drug rationale inhibits X clinical therapy calls, lucitanib encouraging data proangiogenic a of as inhibitor. combination believe in on of pathways As a of similar there's the in studies combination prior this receptors. when targeting the very same PD-X and with X driven PDGF perhaps provides
collaboration our pleased which have from part Ib/II We lucitanib. lucitanib combinations for the gynecological the tumors. study that we Opdivo, to to expansion of now in combination time Clovis-sponsored quarter, preliminary the Squibb clinical announce and a is study Bristol-Myers with SEASTAR now Phase is XXXX. rucaparib-lucitanib with and to that of initiated solid Last this in We're data combination ASCO of have with announced Opdivo we study other enrolling very planned include of in hope
As a patent course, the and including in terms including composition in of be -- patents extensions, similar. protections lucitanib, of globalized And lucitanib's will, U.S. IP, reminder, excluding in EU from China. have expires not XXXX, matter of we
on please of overview preclinical Presentations our Events and For lucitanib, visit the page website.
over turn call discuss XXXX the Dan to quarter I'll to that, financial with results. second And
